Recombinant Human Platelet-Derived Growth Factor-BB and Beta-Tricalcium Phosphate (rhPDGF-BB/B-TCP): An Alternative to Autogenous Bone Graft

Four hundred and thirty four patients in need of either an ankle or hindfoot arthrodesis were randomized to undergo the procedure using either the recombinant human (rh) PDGF-BB/TCP or autograft as bone fusion promoters to determine the non-inferiority of rhPDGF-BB/TCP. Results indicated that rhPDGF-BB/TCP proved to be non-inferior to autograft with respect to fusion rates, clinical union, radiographic union, pain, quality of life, and functional outcomes. Furthermore, rhPDGF-BB/TCP was equally, if not more, safe compared to autograft, with no significant differences between the two groups in terms of complications and adverse events.